Business Wire

Economic and Financial Market Research Veterans Launch New Independent Research Firm Alpine Macro to Provide Global Investors With ‘A Unique Mind on the Markets’

Jaa

Macroeconomic and financial market research veterans Chen Zhao, Tony Boeckh and David Abramson have partnered to launch Alpine Macro – an independent research firm dedicated to providing unique analysis, insights, forecasts and actionable investment strategy recommendations.

Chen, former Chief Global Strategist with BCA Research Group and more recently Co-Director of Global Macro Research with Brandywine Global Investment Management, Boeckh, former Chairman and Editor-in-Chief of BCA, and Abramson, former Chief U.S. Strategist with BCA, will focus on providing differentiated market insights, contrarian views and profitable investment strategy recommendations that help investors manage risk and make better informed investment and asset allocation decisions.

“I am very excited to be partnering with Tony and Dave; we are a group of like-minded people who are intensely curious about global financial markets and love to figure out the key forces and themes that dictate market trends,” says Chen. “Our goal is to provide exceptional research and well-articulated rationale for all of our recommendations.”

“Now more than ever, investors need big-picture analysis to help guide their investment decisions,” says Boeckh. “I am thrilled to be working with Chen and Dave again to provide in depth macroeconomic research and analysis to capture the key inflection points in the markets.”

“Our aim is to help investors cut through the noise and provide them with macro insights and analysis that helps to shape and guide their investment process,” says Abramson. “Combined with our proprietary indicators and models, our objective is to provide consistent, sound analysis, context and perspective on global financial markets.”

Alpine Macro publishes investment research on a weekly basis. The publications include the Alpine Global Strategy and Alpine Macro Monthly reports. The service includes Weekly Reports, Special Reports, Feature Reports, Idea Alerts, Asset Allocation, Quarterly Outlook Reports and Webcasts.

Please contact info@alpinemacro.com to request a trial subscription or receive more information on Alpine Macro’s service.

About Alpine Macro: Founded in 2017, Alpine Macro is an independent global investment research firm based in Montreal, providing market insights and analysis. Alpine Macro focuses on the analysis of major macro-economic forces and specializes in forecasting the direction of global financial markets, while providing actionable recommendations on investment strategy and asset allocation.

Contact information

Alpine Macro
Jeremy Wiseman, +1-514-558-1414 ext. 1
Managing Director
+1-833-7-ALPINE (North America Toll Free)
Jeremy@alpinemacro.com
or
For media inquiries:
Goldman Communications
Keera Hart, +1-416-322-2863
Senior Account Director
keera@goldman-communications.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

New Data Demonstrates Long-Term Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis Treated with Janssen’s TREMFYA® (guselkumab)19.2.2018 11:00Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA® (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.1 Findings from the study also demonstrated that a vast majority of patients originally randomised to guselkumab, but withdrawn from treatment at week 28, regained a PASI 90 response within six months of initiating guselkumab retreatment.1 These long-term findings from the Phase III VOYAGE 2 study were presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, during a late-breaking abstract session at 1:00 PM PST (22:00 CET) on Saturday 17 February. “The longer-term data from VOYAGE 2 shows promising results for guselkumab as both a continuous, long-term treatment for mod

Customers of Palau Telecoms to Enjoy ‘Always On’ Connectivity with SES Networks19.2.2018 10:50Tiedote

Customers of Palau’s local internet services provider Palau Telecoms will continue to enjoy enhanced and reliable fibre-like connectivity delivered by SES Networks. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180218005047/en/ Customers of Palau Telecoms to Enjoy ‘Always On’ Connectivity with SES Networks (Photo: Business Wire) SES announced today that in the latest contract signed, Palau Telecoms, which has been enjoying SES’s Networks exceptional networks performance since 2014, will be extending its contract until 2020, and increasing the amount of medium earth orbit (MEO) connectivity by 150%. A long-term customer of SES Networks, Palau Telecoms is utilising their existing MEO service to augment fibre capacity, providing an ‘always on’ service to its customers. This enhanced, robust infrastructure provides a solid foundation for their 4G implementation plans, giving their end users the quality experience they demand reg

New data presented at the American Academy of Dermatology show LEO Pharma’s Kyntheum® (brodalumab) improves psoriasis on the nail19.2.2018 09:00Tiedote

NOT FOR DISTRIBUTION IN THE UNITED STATES OR UNITED KINGDOM: LEO Pharma today announced new data demonstrating long-term improvements in psoriasis on the nail with Kyntheum® (brodalumab) when compared to placebo or ustekinumab.1 Psoriasis on the nail, which is challenging to treat,2 affects approximately half of the estimated 125 million people living with psoriasis worldwide.2,3 The data were presented at the 76th annual American Academy of Dermatology (AAD) meeting in San Diego, California, US. Psoriasis is a common, chronic, immune-mediated, inflammatory disease that primarily involves the skin, but also impacts emotional, psychological and physical health.4 The heavy and far-reaching burden of the disease can be disabling and stigmatising with a substantial negative impact on those affected and their families.4 Due to the visible nature of the condition, psoriasis on the nail can be particularly upsetting for patients.4 In moderate to severe cases, psoriasis on the nail can be pain

OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers18.2.2018 00:00Tiedote

Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im

CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 11:00Tiedote

Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates

Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 21:26Tiedote

Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme